Stryker Co. (NYSE:SYK) Position Lifted by Fmr LLC

FMR LLC increased its position in shares of Stryker Co. (NYSE:SYK) by 6.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,934,622 shares of the medical technology company’s stock after purchasing an additional 353,028 shares during the quarter. FMR LLC owned 1.59% of Stryker worth $930,251,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. ERTS Wealth Advisors LLC bought a new stake in Stryker in the fourth quarter valued at $25,000. Northwest Wealth Management LLC lifted its stake in Stryker by 103.6% in the fourth quarter. Northwest Wealth Management LLC now owns 169 shares of the medical technology company’s stock valued at $26,000 after buying an additional 86 shares during the last quarter. Semmax Financial Advisors Inc. bought a new stake in Stryker in the fourth quarter valued at $28,000. Horan Securities Inc. bought a new stake in Stryker in the fourth quarter valued at $30,000. Finally, Truehand Inc bought a new stake in Stryker in the fourth quarter valued at $30,000. Hedge funds and other institutional investors own 74.61% of the company’s stock.

NYSE:SYK traded up $0.02 during mid-day trading on Friday, reaching $180.26. 3,396,733 shares of the stock were exchanged, compared to its average volume of 1,243,721. The firm has a market cap of $67.26 billion, a P/E ratio of 24.66, a PEG ratio of 2.19 and a beta of 0.88. Stryker Co. has a 1-year low of $144.75 and a 1-year high of $199.85. The company has a quick ratio of 1.41, a current ratio of 2.02 and a debt-to-equity ratio of 0.72.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.15 by $0.03. The firm had revenue of $3.80 billion for the quarter, compared to analyst estimates of $3.73 billion. Stryker had a return on equity of 27.60% and a net margin of 26.12%. Sell-side analysts expect that Stryker Co. will post 8.13 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 1.15%. The ex-dividend date of this dividend is Thursday, March 28th. Stryker’s payout ratio is currently 28.45%.

In related news, VP Yin C. Becker sold 15,240 shares of the stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $198.03, for a total value of $3,017,977.20. Following the completion of the transaction, the vice president now owns 16,577 shares in the company, valued at approximately $3,282,743.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Timothy J. Scannell sold 4,666 shares of the stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $192.40, for a total value of $897,738.40. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 130,455 shares of company stock worth $24,723,292. 7.20% of the stock is owned by corporate insiders.

SYK has been the topic of a number of recent research reports. Morgan Stanley cut their target price on Stryker from $212.00 to $197.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 2nd. SunTrust Banks raised their price target on Stryker to $205.00 and gave the company a “positive” rating in a report on Monday, February 4th. Royal Bank of Canada raised their price target on Stryker from $184.00 to $204.00 and gave the company an “outperform” rating in a report on Monday, March 11th. Credit Suisse Group raised Stryker to an “outperform” rating in a report on Thursday, January 31st. Finally, Wells Fargo & Co raised their price target on Stryker from $214.00 to $219.00 and gave the company an “outperform” rating in a report on Monday, April 1st. Nine investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $192.13.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/21/fmr-llc-has-930-25-million-stake-in-stryker-co-syk.html.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: Why is the LIBOR significant?

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.